Stevens Capital Management LP Nektar Therapeutics Transaction History

Stevens Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 21, 2020	SELL	$14.47 - $27.96 $168,083 - $324,783	-11,616 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$15.87 - $23.12 $184,345 - $268,561	11,616 New	11,616 $251,000
Q4 2018 Feb 06, 2019	SELL	$30.43 - $56.65 $1.84 Million - $3.43 Million	-60,558 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $1.95 Million - $2.87 Million	41,914 Added 224.81%	60,558 $3.69 Million
Q2 2018 Aug 09, 2018	SELL	$46.25 - $104.45 $9,712 - $21,934	-210 Reduced 1.11%	18,644 $910,000
Q1 2018 May 08, 2018	BUY	$57.4 - $108.44 $1.08 Million - $2.04 Million	18,854 New	18,854 $2 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.